Traws Pharma, Inc. announced on February 28, 2025, that it has received confirmation from Nasdaq regarding its regained compliance with the minimum stockholders’ equity requirements of Nasdaq Listing Rule 5550(b)(1). This rule mandates listed companies to maintain a minimum of $2.5 million in stockholders’ equity.
The company's common stock will continue to be listed and traded on The NASDAQ Capital Market under the symbol “TRAW.” This compliance follows a hearing held on November 14, 2024, and the successful closing of a $20 million financing on December 30, 2024.
Traws Pharma will be subject to mandatory panel monitoring through February 25, 2026. The company's CEO, Werner Cautreels, stated that achieving this milestone and strengthening the company's financial position are important steps towards developing novel antivirals, with an initial focus on bird flu and influenza.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.